SABS Stock Forecast: SAB Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.81
−3.44% on the day

The median 12-month analyst price target for SAB Biotherapeutics, Inc. is $12. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 47 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$253.1M
Ticker Nerd rank
47/ 100
Median analyst target
$12
Analysts covering
11
Revenue$0.0
Operating income−$23.4M
Net income−$22.5M
Free cash flow−$11.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.1%
1M
−2.4%
YTD
−24.9%
1Y
−26.1%
From 52W high
−38.8%
From 52W low
+12.9%
$2.49
$4.59
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores SAB Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
47/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
81
Quality
66
Revisions
60
Momentum
57
Value
40
Growth
38
Issuance
31
Accruals
30

Volatility (81): The share price has been relatively steady.

Accruals (30): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SABS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SABS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26SABSHigh $16Median $12Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
11
Buy
0
Hold
0
Sell
$6
Low
$12
Median
$16
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 June 2026BarclaysInitiatesOverweight$13
17 June 2026Chardan CapitalMaintainsBuy$14 → $16
15 June 2026HC Wainwright & Co.ReiteratesBuy—
15 June 2026Leerink PartnersMaintainsOutperform—
22 May 2026CitigroupInitiatesBuy—
20 May 2026JefferiesInitiatesBuy—
12 May 2026HC Wainwright & Co.MaintainsBuy—
11 May 2026Rodman & RenshawReiteratesBuy—
2 Apr 2026Rodman & RenshawInitiatesBuy—
11 Mar 2026Chardan CapitalMaintainsBuy—
10 Mar 2026HC Wainwright & Co.MaintainsBuy—
7 Jan 2026UBSInitiatesBuy—
19 Dec 2025GuggenheimInitiatesBuy—
18 Dec 2025Chardan CapitalMaintainsBuy—
17 Nov 2025Chardan CapitalMaintainsBuy—
19 Sept 2025Chardan CapitalMaintainsBuy—
17 Sept 2025Leerink PartnersInitiatesOutperform—
8 Aug 2025Chardan CapitalMaintainsBuy—
22 July 2025HC Wainwright & Co.MaintainsBuy—
15 May 2025Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SABS.

Market Radar

This page is one stock. Monday covers all of them.

SABS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SABS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, SAB Biotherapeutics, Inc. returned −26.1% against +6.9% for the S&P 500, dividends included.

SABS vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26SABSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SABS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
1.2×

Cheaper than 64% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−42.8%

Higher than 24% of US stocks

Return on assets
−25.4%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • SAB Biotherapeutics, Inc. has a market value of $253.1M and an enterprise value of $154.0M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$12.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$57.4M.

  • Shares outstanding: 83.5M.

  • SAB Biotherapeutics, Inc. employs 86 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

SABS and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SABSSAB Biotherapeutics, Inc.$253.1M47
EIKNEikon Therapeutics, Inc.$256.4M5
PRLDPrelude Therapeutics, Inc.$257.3M92
KYTXKyverna Therapeutics, Inc.$257.5M34
ALTAltimmune, Inc.$258.5M11
EDITEditas Medicine, Inc.$251.7M67
OCGNOcugen, Inc.$259.9M43

Take a look at SABS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own SAB Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about SABS

What is the SABS stock price forecast for 2026-2027?

The median 12-month analyst price target for SAB Biotherapeutics, Inc. is $12, with estimates ranging from $6 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SABS stock a buy right now?

Of the 11 analysts covering SAB Biotherapeutics, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SAB Biotherapeutics, Inc. 47 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SABS?

As at 21 Nov 2026, SAB Biotherapeutics, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (81 of 100).

Will SABS stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts is $12, and Ticker Nerd's factor model ranks SAB Biotherapeutics, Inc. 47 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SABS stock forecast for 2030?

No analyst covering SAB Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SABS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $16 over the next 12 months.

How has SABS stock performed over the past year?

SAB Biotherapeutics, Inc. returned -26.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does SAB Biotherapeutics, Inc. do?

SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing fully human polyclonal immunotherapies for immune and autoimmune disorders, as well as infectious diseases. The company’s platform is designed to produce high-potency antibody therapies without relying on human donors or convalescent plasma, using a proprietary approach to generate targeted immunoglobulins.

Company

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing fully human polyclonal immunotherapies for immune and autoimmune disorders, as well as infectious diseases. The company’s platform is designed to produce high-potency antibody therapies without relying on human donors or convalescent plasma, using a proprietary approach to generate targeted immunoglobulins. Its current pipeline is centered on SAB-142, a lead product candidate being developed for autoimmune type 1 diabetes. SAB Biotherapeutics Inc. also applies its DiversitAb platform to create multi-target antibody medicines intended for difficult-to-treat conditions across immunology and infectious disease. Based in the United States, the company operates in the biotechnology sector, where it contributes to the development of next-generation antibody-based treatments for patients with significant unmet medical needs.

CEO Mr. Samuel J. Reich · 86 employees · United States · https://www.sab.bio